Since she took OzempicClaire finishes her two glasses of wine in the evening without feeling the same warmth in her cheeks or the same fluttering. On the networks, users talk about feeling “Ozempic sober”: less drunk, less attracted by the aperitif, sometimes disgusted by the very idea of drinking. Some see it as a superpower, others are concerned about a still poorly understood effect of these drugs.
These treatments, called agonists GLP‑1are initially prescribed against diabetes or obesity, and their success for weight loss has triggered a wave of misuses. Studies are now beginning to show that they also change the way the body absorbs alcohol and the way the brain perceives the reward. To the point that some researchers are testing them as future drugs for alcohol withdrawal. Only one certainty: this particular “sobriety” deserves attention.
Ozempic, GLP-1 and alcohol: what happens in the body?
In a small pilot study conducted in Virginia, 20 obese adults were asked to drink an amount of alcohol calibrated to achieve approximately 0.08% blood alcohol content. Half were already taking a GLP-1 drug such as semaglutide, tirzepatide or liraglutide, the other half were not. All had eaten an identical snack, then downed their drink within ten minutes, before a series of repeated measurements of blood pressure, blood sugar and breath alcohol levels.
Result: everyone reaches this threshold, but in people on GLP-1, blood alcohol levels rise more slowly and the feeling of drunkenness remains lower. Which can be problematic, as Alex DiFeliceantonio, assistant professor and interim co-director of the Center for Health Behavior Research at Virginia Tech, points out: “Why is this important? Faster-acting drugs have higher abuse potential“. In other words, slowing down the arrival of alcohol in the blood shifts the feeling of intoxication or reduces it, which could encourage drinkers to consume more if that is what they are looking for.
Ozempic, GLP‑1 and alcohol: why the desire decreases
Conversely, GLP-1 agonists do not only affect digestion. Neurobiological work shows that they bind to receptors present in several areas of the reward system, such as the nucleus accumbens and the ventral tegmental area. They attenuate dopaminergic signals triggered by alcohol and strengthen certain GABA-type inhibitory transmissions. This cocktail makes taking drugs or alcohol less rewarding and can reduce impulsivity linked to the desire to consume.
In humans, cohort studies of tens of thousands of obese patients treated with semaglutide suggest a halving of alcohol-related disorder diagnoses. A randomized clinical trial published in JAMA Psychiatry followed for nine weeks around fifty adults with moderate alcohol use disorder. As a result, semaglutide significantly reduced the participants’ alcohol consumption as well as their “cravings”, i.e. their uncontrollable desires to drink.
Being “Ozempic sober”: good news or false friend?
In the controlled trial, the total number of days participants drank alcohol didn’t really change, but they had fewer drinks on drinking days and experienced fewer binge drinking episodes. Nearly 40% of people taking semaglutide no longer had a heavy drinking day compared to 20% in the placebo group. Signals considered very encouraging by several addiction specialists, even if the sample remains modest and the follow-up is short.
However, the agonists of GLP‑1 are not currently authorized as treatments for alcohol use disorder, and remain reserved for diabetes and certain cases of obesity. Specialists insist on caution: frequent digestive effects, sometimes significant weight loss and shortages linked to massive craze do not advocate self-medication.